State Of Wyoming Veracyte, Inc. Transaction History

State Of Wyoming

$676 Million
Q3 2024

A detailed history of State Of Wyoming transactions in Veracyte, Inc. stock. As of the latest transaction made, State Of Wyoming holds 2,869 shares of VCYT stock, worth $119,178. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,869

Previous 2,635 8.88%

Holding current value

$119,178

Previous $57,000 70.18%

% of portfolio

0.01%

Previous 0.01%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.0 - $35.25 $4,914 - $8,248	234 Added 8.88%	2,869 $97,000
Q2 2024 Aug 14, 2024	BUY	$18.86 - $23.55 $5,507 - $6,876	292 Added 12.46%	2,635 $57,000
Q1 2024 May 13, 2024	BUY	$21.0 - $29.1 $11,319 - $15,684	539 Added 29.88%	2,343 $51,000
Q4 2023 Feb 14, 2024	BUY	$19.72 - $28.68 $4,456 - $6,481	226 Added 14.32%	1,804 $49,000
Q3 2023 Nov 14, 2023	BUY	$22.33 - $29.92 $11,522 - $15,438	516 Added 48.59%	1,578 $35,000
Q2 2023 Aug 14, 2023	BUY	$20.96 - $26.99 $5,826 - $7,503	278 Added 35.46%	1,062 $27,000
Q1 2023 May 12, 2023	BUY	$20.58 - $27.89 $2,798 - $3,793	136 Added 20.99%	784 $17,000
Q4 2022 Feb 14, 2023	BUY	$15.31 - $29.94 $45 - $89	3 Added 0.47%	648 $15,000
Q3 2022 Nov 14, 2022	SELL	$16.58 - $27.9 $414 - $697	-25 Reduced 3.73%	645 $11,000
Q2 2022 Aug 15, 2022	SELL	$15.45 - $29.52 $16,485 - $31,497	-1,067 Reduced 61.43%	670 $13,000
Q4 2021 Feb 11, 2022	SELL	$36.09 - $53.79 $1,840 - $2,743	-51 Reduced 2.85%	1,737 $72,000
Q3 2021 Feb 11, 2022	BUY	$35.62 - $52.97 $28,317 - $42,111	795 Added 80.06%	1,788 $83,000
Q2 2021 Feb 11, 2022	BUY	$32.94 - $56.62 $32,709 - $56,223	993 New	993 $40,000

Others Institutions Holding VCYT

# of Institutions

307

Shares Held

81.6M

Call Options Held

134K

Put Options Held

13.3K

View Full List

About VERACYTE, INC.

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

More about VCYT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.

Account